A medication-adherence study conducted by HITLAB, found approximately 90% of participants reported forgetting to take their medication at some point along their treatment path. Of this, 80% of study participants also reported having missed multiple doses. However, after interacting with the IMC’s eCAP smart pill bottle and companion phone app, CertiScan®, approximately 80% of the study participants found the technology helpful in their daily lives. Additionally, half of the study participants reported that they would recommend the technology to a family or friend. For researchers and public health advocates, insight gained from such efforts points toward broad impacts at local, national, and even global levels.
A large application for such technology, in both consumer health and clinical trials, would provide valuable clues toward population morbidity and mortality rates, such as among cancer patients or people with opioid dependence. Despite this, a consensus still does not exist among researchers, patients, and legislative bodies as to whether a best practice, ethical, regulatory, or legal standard exists. However, a consensus has begun to emerge that medication-adherence technology stands out as a strong intervention toward improving not just individual health, but public health within local and global communities. Therefore, continued engagement with consumers and patients, in both the consumer health and clinical trials spaces, is vital towards its adoption and application.